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As companies focus on an aging 
population, they are finding that it is 
more difficult to get a handle on the 
causes of disease. Where once there 
were defined single causes such as 
bacteria, there are now the variable 
and multitudinous risk factors for 
cancer and heart disease. 
And then there are the 
degenerative diseases, in which the 
body has simply run out of steam. 
MitoKor, based in San Diego, 
California, is working on the 
assumption that it is the mitochondria 
that fall first, or at least hard, in some 
of these diseases, such as Alzheimer’s 
disease (AD) and Parkinson’s disease 
(PD). The theory is supported by an 
attractive model that could explain 
the sporadic nature of the diseases, 
and by evidence of mitochondrial 
dysfunction. But a verdict on whether 
this dysfunction is real or relevant 
may have to wait for clinical trials of a 
drug that does not yet exist. 
Effects of defective mitochondria 
MitoKor began in 1991, as Applied 
Genetics. It was based on the work 
of W. Davis Parker, who was at that 
time a pediatric neurologist at the 
University of Colorado. “He had 
observed similarities in the pathology 
and history of diseases of the very 
young and very old,” says Walter 
Moos, formerly of Chiron and now 
the CEO of MitoKor. “This was 
traced to energetic deficiencies and 
ultimately to mitochondria.” 
“A lot of people have always 
believed that mitochondria are so 
critical that almost any significant 
defect would be fatal,” says Moos. 
Something close to that was 
happening in the rare pediatric cases 
- a mutation in an energy- 
generating pathway was causing 
rapid and drastic deterioration. The 
adult patients reached a similar 
point, but only at an advanced age 
and after many years of slow disease 
progression. Perhaps, thought Parker, 
the adult diseases were less severe 
versions of the pediatric diseases. 
It is not surprising that 
mitochondria should be the first part 
of the cell to wear out. Respiration is a 
dangerous process, involving the 
transfer of electrons from one carrier 
molecule to another. The electrons’ 
destination is molecular oxygen; in the 
final reaction they are used to reduce 
it to water. But if there is a block in 
the electron-transport chain, or if one 
component is more active than the 
next component, the stray electrons 
can damage the mitochondrion. Most 
often the electrons help form reactive 
oxygen species (ROS), which can 
damage proteins, DNA and 
membranes. Damage to the 
membranes can short-circuit the 
charge gradient needed for ATP 
production, and release pro-apoptotic 
molecules like cytochrome c that can 
trigger programmed cell death. 
Explaining sporadic disease 
Mitochondria as a cause of late-onset, 
sporadic disease makes sense. The 
late onset is consistent with a gradual 
buildup of damage, which should be 
at its most severe in cells with high 
energy requirements and little or no 
cell division to dilute the damage. 
And sporadic disease could be 
explained by the idiosyncrasies of 
mitochondrial DNA inheritance. 
Although neither AD nor PD 
shows anything like strict Mendelian 
inheritance, there is some clustering 
of the diseases in families. For both 
diseases, individuals with affected 
mothers are at greater risk; this is 
consistent with maternal inheritance 
of a mitochondrial DNA mutation. 
Any given cell of any given 
individual may have several different 
mitochondrial genomes, a condition 
termed heteroplasmy. There is 
stochastic inheritance of these 
different genomes in the cell divisions 
of both oocytes (leading to differences 
between siblings and even ‘identical’ 
twins) and somatic cells (leading to 
mosaicism and tissue-specific effects). 
Varying dosages of these different 
genomes could explain variation in the 
time and severity of disease onset. 
The physical evidence 
A theory is all very well, but a 
company needs hard evidence. 
Parker, who is now based at the 
University of Virginia, found in 1990 
that AD patients had a defect in 
complex IV of the electron-transport 
chain; the previous year he found that 
PD patients had a defect in complex 
I. The latter defect is consistent with 
an animal model of PD, which relies 
on the use of N-methyl-4-phenyl- 
1,2,3,6-tetrahydropyridine (MPTP) to 
inhibit NADH:ubiquinone 
oxidoreductase, a component of 
complex I. And the fact that the ttio 
disease defects are distinct, and hold 
true outside of the brain, give Parker 
and MitoKor confidence that they are 
not looking at a nonspecific response 
to cell death in the brain. 
Not everyone is so confident. 
“I’m of an open mind,” says David 
Clayton, of the Howard Hughes 
Medical Institute in Chevy Chase, 
Maryland. “I don’t believe [the 
possible importance of mitochondria] 
has been ruled out, particularly as a 
secondary consequence.” 
Eric Shoubridge of McGill 
University (Montreal, Canada) is also 
unsure. “There’s no general 
agreement on whether [these effects] 
are real or not real, or primary or 
secondary,” he says. “If there was 
clearly a strong dependency [of 
disease on mitochondria] I think 
there would be strong agreement.” 
The clincher would be a specific 
mitochondrial mutation, presumably 
in complex IV genes. In the April 
1997 Proceedings of the Natiolzal 
Academy of Sciences, Parker and 
MitoKor reported that AD patients 
R304 Chemistry & Biology 1998, Vol5 No 11 
had a higher incidence of five 
missense mutations: two in 
cytochrome c oxidase (CO) subunit I 
and three in CO subunit II. Any given 
patient had a mixture of the ‘mutant’ 
and wild-type sequence, but this 
could be explained by heteroplasmy. 
picking responders,” says Moos, “but 
none of the drugs in studies we have 
completed to date have worked well 
enough to find an effect.” 
The size of the difference was not 
huge - approximately 1845% 
mutant sequence for AD patients, 
compared to approximately 12~15% 
for controls - but it allowed the 
researchers to identify 20% of the AD 
patients who had levels of the mutant 
allele exceeding those of any control 
case. Sixty percent of AD patients, 
but only 20% of control subjects, had 
over 20.3% mutant alleles. 
The result began to unravel in the 
very same paper, in a note added in 
proof. The authors spotted their 
mutant alleles in databases of the 
wild-type mitochondrial DNA 
sequences of several of the great 
apes, raising the question of whether 
all great apes carry an AD mutation. 
The answer came in December 
1997 from Douglas Wallace (Emory 
University, Atlanta, Georgia) and 
Eric Schon (Columbia University, 
New York). They found that the 
‘mutant alleles’ were pseudogenes in 
the nucleus; the difference between 
diseased and control presumably 
reflected decreased mitochondrial 
copy number in those with AD. 
“There do appear to be changes 
in the mitochondrial DNA that track 
with the disease,” says Moos. “It 
could be absolute [genome] loss, or 
mutations that we haven’t found. It’s 
possible that each individual has a 
different set of mutations.” 
Whatever the explanation, he says, 
“the test we have still associates with 
the disease.” This primer extension 
assay measures the relative copy 
number of the mitochondrial genes 
and the nuclear pseudogenes (i.e., the 
mitochondrial DNA copy number). 
MitoKor sells use of the test to 
pharmaceutical companies who are 
running trials of their AD drug 
candidates; the test is now being used 
in the sixth trial of this type. “We’re 
trying to determine if it is useful in 
Finding drugs 
One of MitoKor’s key technologies is 
its ‘cybrid’ cell lines. These lines are 
made by fusing diseased, anucleate 
cells (such as platelets from an AD 
patient) with normal, nucleated cells 
that lack mitochondria. By 
transferring AD mitochondria, 
MitoKor also transfers AD traits such 
as decreased cytochrome oxidase 
activity, increased ROS production, 
and increased production of 
B-amyloid, the protein fragment that 
aggregates in AD brains. MitoKor has 
developed a similar cellular model for 
PD and type II diabetes. 
Before the Wallace and Schon 
papers, MitoKor believed it was 
transferring mutant complex IV 
genes with the AD mitochondria, but 
now the story appears to be more 
complicated. “These papers put the 
ball back in the company’s court to 
explain the cybrid data, and what is 
being transferred,” says Shoubridge. 
Meanwhile, MitoKor is looking for 
differences in protein expression 
between cybrids with normal and AD 
mitochondria. These differences could 
be exploited in diagnostic tests, or the 
proteins could be future drug targets. 
But Moos’s main interest is in 
using the cybrids as cellular models 
of disease, for finding and testing 
drug candidates. “It’s clear that the 
activity level of complex IV is 
decreased, perhaps because of an 
incorrect stoichiometry [only three of 
the thirteen subunits are encoded in 
mitochondria]. So we’ve focused on 
the ultimate level of function.” 
That ultimate readout is the status 
of the mitochondrial permeability 
transition pore (PTP). The PTP is 
defined more by its electrical behavior 
than its molecular composition: when 
it opens it releases ions and 
metabolites and the respiratory chain 
collapses. MitoKor’s task is to improve 
mitochondrial function and thus 
forestall the opening of the PTF! 
“We’ve found a number of targets 
that influence the [mitochondrial 
permeability] transition or apoptosis,” 
says Moos. “We don’t typically go 
after the electron-transport chain 
itself, as we would have to improve 
enzyme activity.” But MitoKor is 
testing some defined (but 
undisclosed) protein targets, in 
addition to doing whole-cell assays. 
Animal testing of candidate 
molecules has been started. 
Are mitochondria the answer? 
“Alzheimer’s disease, like many 
diseases, is not one disorder, it’s 
several,” says Moos. “People will 
agree or disagree [with the importance 
of mitochondria] based on their own 
personal research because this is not 
one disease. I would characterize it as 
at least three different disorders which 
all present with the same symptoms.” 
MitoKor does not assert that their 
mitochondrial theory will explain all 
AD and PD; their estimate is closer 
to 50%. Moos says the same may be 
true for type II diabetes. “As with 
Alzheimer’s disease, I’m not sure 
that anyone has this all together yet, 
other than their particular bias.” 
“One of the things I’ve been 
amazed about is how complicated 
these diseases really are and how 
much difference of opinion there is as 
to what is primary versus secondary,” 
he says. “It’s far from clear what the 
primary events are. And it’s not 
terribly relevant whether 
mitochondria are primary or 
secondary, if you can treat the disease 
by treating the mitochondrial defect.” 
MitoKor would be happy to link a 
mitochondrial mutation to AD, but 
Moos says it is not essential. “It’s 
easiest to sell the story if you have 
the mechanism all the way back to 
the genetics,” he says. “But there are 
certainly a lot of drugs that have 
made it to market with an unknown 
mechanism. At the end of the day 
the big ticket is the drug.” 
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